Literature DB >> 21922345

Malfunctioning DNA damage response (DDR) leads to the degeneration of nigro-striatal pathway in mouse brain.

Michal Kirshner1, Ronit Galron, Dan Frenkel, Gil Mandelbaum, Yosef Shiloh, Zhao-Qi Wang, Ari Barzilai.   

Abstract

Pronounced neuropathology is a feature of ataxia-telangiectasia (A-T) and Nijmegen breakage syndrome (NBS), which are both genomic instability syndromes. The Nbs1 protein, which is defective in NBS, is a component of the Mre11/RAD50/NBS1 (MRN) complex. This complex plays a major role in the early phase of the cellular response to double strand breaks (DSBs) in the DNA. Among others, MRN is required for timely activation of the protein kinase ATM (A-T mutated), which is disrupted in patients with A-T. Earlier reports show that Atm-deficient mice exhibit severe degeneration of tyrosine hydroxylase (TH)-positive dopaminergic nigro-striatal neurons and their terminals in the striatum. This cell loss is accompanied by a large reduction in immunoreactivity for the dopamine transporter protein (DAT) in the striatum. To test whether Nbs1 inactivation also affects the integrity of the nigro-striatal pathway, we examined this pathway in a murine model with conditional inactivation of the Nbs1 gene in central nervous system (Nbs1-CNS-Δ). We report that this model has a reduction in TH-positive cells in the substantia nigra. This phenomenon was seen at very early age, while Atm-/- mice showed a progressive age-dependent reduction. Furthermore, we observed an age-dependent increase in the level of TH in the striatum of Atm-/- and Nbs1-CNS-Δ mice. In addition to the altered expression of TH, we also found a reduction of DAT in the striatum of both Atm-/- and Nbs1-CNS-Δ mice at 60 days of age. Finally, microglial recruitment and alterations in the levels of various neurotrophic factors were also observed. These results indicate that malfunctioning DNA damage response severely affects the integrity of the nigro-striatal pathway and suggest a new neurodegenerative pathway in Parkinsonian syndromes.

Entities:  

Mesh:

Year:  2011        PMID: 21922345     DOI: 10.1007/s12031-011-9643-y

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  95 in total

Review 1.  The cellular response to general and programmed DNA double strand breaks.

Authors:  Craig H Bassing; Frederick W Alt
Journal:  DNA Repair (Amst)       Date:  2004 Aug-Sep

2.  Purkinje cell loss in the cerebellar flocculus in patients with ataxia with ocular motor apraxia type 1/early-onset ataxia with ocular motor apraxia and hypoalbuminemia.

Authors:  Masashiro Sugawara; Chizu Wada; Satoshi Okawa; Michio Kobayashi; Masato Sageshima; Tsuyoshi Imota; Itaru Toyoshima
Journal:  Eur Neurol       Date:  2007-10-04       Impact factor: 1.710

3.  Investigation of the functional link between ATM and NBS1 in the DNA damage response in the mouse cerebellum.

Authors:  Inbal Dar; Galit Yosha; Ronen Elfassy; Ronit Galron; Zhao-Qi Wang; Yosef Shiloh; Ari Barzilai
Journal:  J Biol Chem       Date:  2011-02-07       Impact factor: 5.157

4.  Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma.

Authors:  Y Xu; T Ashley; E E Brainerd; R T Bronson; M S Meyn; D Baltimore
Journal:  Genes Dev       Date:  1996-10-01       Impact factor: 11.361

Review 5.  Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks.

Authors:  Martin Digweed; Karl Sperling
Journal:  DNA Repair (Amst)       Date:  2004 Aug-Sep

Review 6.  Ataxia-telangiectasia: is ATM a sensor of oxidative damage and stress?

Authors:  G Rotman; Y Shiloh
Journal:  Bioessays       Date:  1997-10       Impact factor: 4.345

Review 7.  Familial breast and ovarian cancers.

Authors:  Masami Arai; Joji Utsunomiya; Yoshio Miki
Journal:  Int J Clin Oncol       Date:  2004-08       Impact factor: 3.402

Review 8.  ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks.

Authors:  M F Lavin
Journal:  Oncogene       Date:  2007-12-10       Impact factor: 9.867

9.  Alternative splicing and mutation status of CHEK2 in stage III breast cancer.

Authors:  Vidar Staalesen; Jacob Falck; Stephanie Geisler; Jirina Bartkova; Anne-Lise Børresen-Dale; Jiri Lukas; Johan Richard Lillehaug; Jiri Bartek; Per Eystein Lønning
Journal:  Oncogene       Date:  2004-11-04       Impact factor: 9.867

10.  Abnormal development of Purkinje cells and lymphocytes in Atm mutant mice.

Authors:  P R Borghesani; F W Alt; A Bottaro; L Davidson; S Aksoy; G A Rathbun; T M Roberts; W Swat; R A Segal; Y Gu
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  5 in total

Review 1.  DNA double-strand breaks: a potential therapeutic target for neurodegenerative diseases.

Authors:  Nidheesh Thadathil; Roderick Hori; Jianfeng Xiao; Mohammad Moshahid Khan
Journal:  Chromosome Res       Date:  2019-11-09       Impact factor: 5.239

Review 2.  The ATM protein kinase: regulating the cellular response to genotoxic stress, and more.

Authors:  Yosef Shiloh; Yael Ziv
Journal:  Nat Rev Mol Cell Biol       Date:  2013-03-13       Impact factor: 94.444

3.  Analysis of Clinical and Genetic Characterization of Three Ataxia-Telangiectasia Pedigrees With Novel ATM Gene Mutations.

Authors:  Peng Huang; Lu Zhang; Li Tang; Yi Ren; Hong Peng; Jie Xiong; Lingjuan Liu; Jie Xu; Yangyang Xiao; Jian Li; Dingan Mao; Liqun Liu
Journal:  Front Pediatr       Date:  2022-05-02       Impact factor: 3.418

4.  Decoding the Role of Familial Parkinson's Disease-Related Genes in DNA Damage and Repair.

Authors:  Yao-Lin Li; Zhong-Xuan Wang; Chang-Zhou Ying; Bao-Rong Zhang; Jia-Li Pu
Journal:  Aging Dis       Date:  2022-10-01       Impact factor: 9.968

Review 5.  Neuroprotective Transcription Factors in Animal Models of Parkinson Disease.

Authors:  François-Xavier Blaudin de Thé; Hocine Rekaik; Alain Prochiantz; Julia Fuchs; Rajiv L Joshi
Journal:  Neural Plast       Date:  2015-12-31       Impact factor: 3.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.